SLU-PP-332
Pan-ERR agonist
SLU-PP-332 (Pan-ERR agonist) is a metabolic & fat loss research compound. Synthetic pan-ERR (α/β/γ) agonist that switches on the endurance-exercise gene program via PGC-1α — mitochondrial biogenesis and fat oxidation, an 'exercise mimetic.'
SLU-PP-332 quick facts
| Reported research dose | 500mcg-1500mcg (Up To .5-4mg/kg) |
| Route | Subq |
| Frequency | 2-3x Daily AM/Mid/PM |
| Half-life | Very short (<1 hr) |
| Forms | Injectable, Oral |
| Evidence level | Mouse only — no human data |
Wildly promising on paper, but it's rodent-stage. Exciting, not proven — say that honestly.
How SLU-PP-332 works
Synthetic pan-ERR (α/β/γ) agonist that switches on the endurance-exercise gene program via PGC-1α — mitochondrial biogenesis and fat oxidation, an 'exercise mimetic.'
Proposed benefits
Endurance and fat oxidation as an 'exercise mimetic' (rodent-stage).
Human clinical evidence
- No human trials. It never left preclinical development, so the ceiling on what anyone can claim is a rodent model — and rodent models of this endpoint have a poor record of transferring.
📊 Correlative data
- Recent arrival to the research market with a very thin practical record. Reported experience is dominated by the injectable route — it has poor oral bioavailability and a short half-life in the animal work, which most sellers do not mention.
- Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 How the mechanism reads
- A pan-ERR agonist — estrogen-related receptors are orphan nuclear receptors that, despite the name, do not bind estrogen. ERRα is a master regulator of mitochondrial biogenesis, working with PGC-1α.
- Mouse work reported increased running endurance and fat loss without exercise and without reducing food intake — an energy-expenditure mechanism rather than an appetite one, which is what makes it interesting against the GLP-1 class.
- Driving mitochondrial biogenesis systemically is not free. More mitochondria means more electron transport and more reactive oxygen species, and the heart is among the most ERR-dense tissues in the body.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
SLU-PP-332 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signalling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signalling reasoning above.
- Pregnancy — uncharacterised.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalogue should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Where to get SLU-PP-332
Buy SLU-PP-332 at Flawless Compounds →SLU-PP-332 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What SLU-PP-332 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for SLU-PP-332 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Needle gauge and injection site
- How the forms differ in dose
- Coach Cam's personal notes
Get the complete breakdown for SLU-PP-332 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →Bloodwork to run alongside SLU-PP-332
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 102 markers A–Z
SLU-PP-332 — frequently asked questions
What is SLU-PP-332?
SLU-PP-332 (Pan-ERR agonist) is a metabolic & fat loss research compound. Synthetic pan-ERR (α/β/γ) agonist that switches on the endurance-exercise gene program via PGC-1α — mitochondrial biogenesis and fat oxidation, an 'exercise mimetic.'
Is the full SLU-PP-332 protocol on this page?
The reported research dose is on this page, along with how SLU-PP-332 works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside the Academy.
What is the half-life of SLU-PP-332?
SLU-PP-332 has an approximate half-life of Very short (<1 hr), which is part of what determines how often it's dosed.
What forms does SLU-PP-332 come in?
SLU-PP-332 is available as: Injectable, Oral.
What's the evidence behind SLU-PP-332?
Current evidence level: Mouse only — no human data. SLU-PP-332 is offered for research purposes only and is not an approved medicine.
Want Coach Cam's exact SLU-PP-332 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What SLU-PP-332 is used for
SLU-PP-332 appears under 2 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.